Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596310 | 0.97 | ALDH1A1 (0.45) | GBA1ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL28702513 | 0.82 | CFD (0.43) | GBA1ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL30994403 | 0.80 | NCEH1 (0.41) | KDM4EACHE | |
| SCHEMBL16715040 | 0.76 | PGR (0.49) | GBA1ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL17596594 | 0.75 | RXRA (0.50) | GBA1ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL5833456 | 0.73 | RXRA (0.49) | ALDH1A1KDM4EHSD17B10LMNAPGR | |
| SCHEMBL5900986 | 0.73 | MEN1 (0.40) | GBA1ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL3594157 | 0.72 | KMT2A (0.51) | ALDH1A1KMT2AKDM4EMAPTMEN1 | |
| SCHEMBL13021618 | 0.72 | ELANE (0.50) | ALDH1A1KDM4EHSD17B10LMNAMAPT | |
| SCHEMBL7206062 | 0.71 | RXRA (0.50) | ALDH1A1KDM4EHSD17B10LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| US-6225480-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | GBA1 1961/4885ALDH1A1 1463/4885KMT2A 1061/4885 |
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | H1-0, H1-2, ASH2L | GBA1 2368/4885ALDH1A1 894/4885KMT2A 173/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | GBA1 1961/4885ALDH1A1 1463/4885KMT2A 1061/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | GBA1 1961/4885ALDH1A1 1463/4885KMT2A 1061/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | GBA1 1961/4885ALDH1A1 1463/4885KMT2A 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.